Methylfolate (5-MTHF): When the Bioactive Form Actually Matters

What is methylfolate?

5-methyl-tetrahydrofolate (5-MTHF) is the active, circulating form of folate (vitamin B9). It is the direct methyl-group donor in the methionine synthase reaction (paired with vitamin B12) that converts homocysteine back to methionine and feeds the entire cellular methylation cycle (SAMe, DNA methylation, neurotransmitter synthesis).

Most folate supplements and food fortification use synthetic folic acid, which is not biologically active until your cells walk it through several steps:

Folic acid → DHF → THF (via DHFR) → 5,10-methylene-THF → 5-MTHF (via MTHFR)

5-MTHF supplements skip all of those steps. That matters in two situations: (1) when DHFR is saturated by high-dose folic acid (the source of "unmetabolized folic acid," or UMFA, in serum), and (2) when MTHFR enzyme activity is reduced by a common genetic variant.

According to the NIH Office of Dietary Supplements, dietary folate equivalents (DFE) are used to compare forms — but in clinical practice, the form on the label only matters for a relatively narrow set of people, which we'll cover below.

Evidence-based benefits of methylfolate

1. MTHFR variants (C677T, A1298C)

The MTHFR enzyme is what your body uses to make 5-MTHF in the first place. The C677T (rs1801133) homozygous variant produces an enzyme with roughly 25–30% lower activity than the wild-type version. Compound heterozygotes (one copy of C677T plus one copy of A1298C) are similarly affected. By taking 5-MTHF directly, you ensure adequate active folate without depending on the partially-reduced enzyme to do the conversion.

2. Treatment-resistant major depression

Adjunctive L-methylfolate 7.5–15 mg/day (Deplin) added to an existing SSRI improved response rates in two SSRI-non-responder MDD trials by roughly 20–30% versus SSRI plus placebo (Papakostas et al., 2012, American Journal of Psychiatry). It is FDA-classified as a medical food, not a drug — meaning it requires a prescription but does not go through the standard NDA pathway. It is an adjunct, not a monotherapy.

3. Hyperhomocysteinemia (in a subset)

Homocysteine is recycled to methionine using a methyl group donated by 5-MTHF. In MTHFR variant carriers in particular, methylfolate may lower elevated homocysteine more reliably than folic acid because conversion is no longer the limiting step.

4. Pregnancy and unmetabolized folic acid concerns

Methylfolate avoids the accumulation of serum UMFA seen with high-dose folic acid intake. The prenatal NTD-prevention evidence base — the foundational trials behind public-health folate fortification — is built on folic acid. But 5-MTHF (typically as Quatrefolic) is increasingly accepted in OB practice, particularly for patients with known MTHFR variants or those who prefer to avoid UMFA. In all cases, folate intake before and during early pregnancy is what matters most.

MTHFR variants explained

Two single-nucleotide polymorphisms get all the attention:

• C677T (rs1801133) — substitutes a valine for an alanine at position 222. Homozygotes (TT) have ~25–30% of normal MTHFR activity. Frequency varies by population: roughly 10% of Caucasians, ~25% of Hispanics, lower in those of African descent.
• A1298C (rs1801131) — produces a smaller reduction in enzyme activity. Most clinically relevant when paired with a C677T allele (compound heterozygote).

Most carriers are completely asymptomatic and do not need testing. Major U.S. professional societies (ACMG, ACOG/SMFM) do not recommend routine MTHFR genotyping. Testing is reasonable in a narrow set of clinical situations:

• Recurrent pregnancy loss, particularly with elevated homocysteine
• Treatment-resistant depression with elevated homocysteine
• Unexplained venous thromboembolism (controversial — most guidelines do not endorse this indication)
• Known family history of severe early-onset cardiovascular disease

For more on what a positive result actually means (and doesn't), see MTHFR Explained.

How much methylfolate should you take?

Forms compared

Typical doses

• General supplementation: 400–1,000 µg/day (most people don't need more than the 400 µg in a standard multivitamin).
• Pregnancy / pre-conception, no MTHFR testing: 400–800 µg/day. With known C677T homozygous: 800–1,000 µg/day.
• MDD adjunct (Rx Deplin): 7.5–15 mg/day under psychiatric supervision, alongside an existing SSRI/SNRI.
• Hyperhomocysteinemia: 1 mg/day, typically alongside B12 and B6.

Side effects

Methylfolate is generally well-tolerated. The most commonly reported issue, especially at higher doses, is initial "overactivation" symptoms — anxiety, irritability, or insomnia — in the first days to weeks of starting. The clinical workaround is simple: start low (200–400 µg) and titrate rather than starting at 1 mg or more.

As with folic acid, methylfolate can mask the hematologic signs of B12 deficiency while neurologic damage progresses. If you supplement folate at any meaningful dose, verify B12 status (serum B12 plus, ideally, methylmalonic acid) — particularly if you are vegan, over 50, on metformin, or on a long-term PPI.

Drug interactions to know about

• Methotrexate — same warning as for folic acid. Concurrent low-dose MTX (rheumatology, dermatology) is generally OK and even helps offset side effects. High-dose oncologic methotrexate uses leucovorin (folinic acid) rescue specifically; do not self-supplement folate during oncologic MTX without your team's input.
• SSRIs and SNRIs — adjunctive use is the indication for Deplin; there are no clinically problematic pharmacokinetic interactions.
• Anti-epileptics (phenytoin, valproate, carbamazepine) — increase folate requirements and can cause folate deficiency. Methylfolate may have less effect on serum anticonvulsant levels than folic acid (limited data). Coordinate with the prescribing neurologist.
• Vitamin B12 — always pair adequate folate with adequate B12 to avoid masking deficiency.

Check our free interaction checker for a complete list.

Frequently asked questions

Related articles